Featured Interviews
UPDATE: Xortx Therapeutics (CSE: XRX) (OTCQB: XRTXF)
Dr. Alen Davidoff provided an update on his previous interview from August 2020. Xortx just announced a recent grant on their European patent as well as other activity in the market. The company is hoping to start on their phase III trial on their autosomal dominant polycystic kidney disease program in the next quarter as well as up-list to a higher-tiered US exchange. […]
